A leading UK medical cosmetic doctor is very impressed by Biodental

A leading UK medical cosmetic doctor is very impressed by Biodental

Source: page2rss.com

Targeting Protein S14 In Breast Cancer Treatment
William Kinlaw, an associate professor of medicine at Dartmouth Medical School, has been working on a protein called S14 since 1990. Over the past few months, however, the news about S14 has picked up. Through a series of recently published academic studies, Kinlaw and colleagues are ready to pronounce S14 a potential drug target in treating breast cancer........
Source: medicineworld.org

If you're looking for implants, traditional or cosmetic dentistry

Source: page2rss.com

MRI Best To Detect Cancer Spread Into Breast Ducts
MRI is better than MDCT for determining if and how far breast cancer has spread into the breast ducts and should be used before patients receive breast conserving treatment, a new study shows. "Patients have a lower survival rate if their surgical margins are positive for tumor cells. A positive surgical margin is commonly the result of inadequate resection of the cancer's intraductal component, " said Akiko Shimauchi, MD, at Tohoku University in Sendai, Miyagi, Japan. "Accurate preoperative diagnosis of the intraductal component allows the surgeon to achieve a cancer-free surgical margin, " she said........
Source: medicineworld.org

International Trial Of Novel Breast Cancer Drug
A clinical trial of a new targeted breast cancer drug, led by physicians at Massachusetts General Hospital (MGH) Cancer Center, has begun enrolling patients. The TEACH (Tykerb Evaluation After CHemotherapy) trial will investigate the experimental drug Tykerb (lapatinib) in patients with early-stage, HER2-positive breast cancer who have not been treated with Herceptin, another targeted drug used for the same type of tumor. The MGH is the lead institution for the international trial, which is being sponsored by GlaxoSmithKline, the manufacturer of Tykerb........
Source: medicineworld.org

Raloxifene as Effective as Tamoxifen in Preventing Breast Cancer
The largest North American breast cancer prevention trial, the Study of Tamoxifen and Raloxifene, or STAR trial, has compiled an initial analysis of study data and found the osteoporosis drug raloxifene works as well as tamoxifen in reducing breast cancer risk for postmenopausal women at increased risk of the disease. Both drugs reduced the risk of developing invasive breast cancer by about 50 percent........
Source: medicineworld.org

Psychological Needs Of Breast Cancer Patients
Almost half of newly diagnosed patients with breast cancer are found to have clinically significant emotional distress or symptoms of psychiatric disorders before therapy is begun, as per a new study reported in the recent issue of CANCER, a peer-evaluated journal of the American Cancer Society. The study reveals that while virtually all of the women admitted to, experiencing some level of emotional distress, 47 percent met clinically significant screening criteria for emotional distress or a psychiatric disorder, including major depression and post-traumatic stress disorder (PTSD)........
Source: medicineworld.org

Social Isolation Has Its Toll In Breast Cancer
A new research has found that women who have few close friends or family members at the time of a breast cancer diagnosis are more likely to die from breast cancer compared to those who have better social support structure. Study author Dr. Candyce H. Kroenke, of the University of California, Berkeley and San Francisco says that social support is very important in breast cancer. Social isolation can lead to a limitation of access to health care, and can lead to inadequate care and may affect the breast cancer outcome........
Source: medicineworld.org

"View our June Special Promotions" >>>

Source: page2rss.com

Gene profiling and resistance to Herceptin
Using gene chips to profile tumors before therapy, scientists at Harvard and Yale Universities found markers that identified breast cancer subtypes resistant to Herceptin, the primary therapy for HER2-positive breast cancer. They say this advance could help further refine treatment for the 25 to 30 percent of patients with breast cancer with this class of tumor........
Source: medicineworld.org